Clinical trials: Heparin-Induced Thrombocytopenia
Heparin-induced Thrombocytopenia (HIT)
Optimizing the Diagnosis of Heparin Induced Thrombocytopenia
Multicentre (Ottawa and Halifax) prospective cohort study using a diagnostic approach in patients clinically suspected to have HIT that combines pretest probability assessment with quantitative interpretation of anti-PF4 assay.
- Trial name
- HIT (NCT03148912)
- Testing
- Diagnostic algorithm
- Where
- Canada
- Volunteers
- 107 people
- Sponsor
- Ottawa Hospital Research Institute
Heparin-Induced Thrombocytopenia
Heparin-Induced Thrombocytopenia Registry
The purpose of the Heparin Induced Thrombocytopenia Registry is to explore the frequency of heparin-induced thrombocytopenia (HIT) at Brigham and Women's Hospital and to assess its mortality rate.
- Trial name
- HIT (NCT00456326)
- Where
- United States
- Volunteers
- 242 people
- Sponsor
- Brigham and Women's Hospital
Heparin Induced Thrombocytopenia
Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study
HIT-RADIO is a study of patients who had a positive heparin PF-4 antibody test between 1/21/2008 and 9/25/2008 at selected hospitals.
- Trial name
- HIT-RADIO (NCT01178333)
- Where
- 21 sites in United States
- Volunteers
- 668 people
- Sponsor
- Carelon Research
Heparin-induced Thrombocytopenia, Liver Transplantation
Heparin-induced Thrombocytopenia (HIT II) in Liver Transplant Recipients
In a prospective observational study the incidence of Heparin-induced Thrombocytopenia (HIT) Type 2 after orthotopic liver transplantation, associated factors, and hemostaseological findings in thrombocytes and anti-body patterns…
- Trial name
- HITOLT (NCT01654848)
- Where
- Germany
- Volunteers
- 39 people
- Sponsor
- CHIR-Net
Heparin Induced Thrombocytopenia (HIT)
Argatroban Versus Lepirudin in Critically Ill Patients
The purpose of this study is to test the hypotheses that argatroban significantly increases efficacy and safety of renal replacement therapy measured as life time of haemodialysis filters as compared to lepirudin
- Trial name
- ALiCia (NCT00798525)
- Testing
- Argatroban, Lepirudin
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Dialysis; Complications, Heparin-induced Thrombocytopenia
Multicenter Study on Dialysis Modalities for End-stage Chronic Renal Failure Patients With Heparin-induced Thrombocytopenia
This research is based on the hypothesis that the Hydrolink®-NV dialysis membrane could allow the realization of quality dialysis with a significant reduction in the doses of Orgaran®, or even a total cessation of the…
- Conditions
- Dialysis; Complications, Heparin-induced Thrombocytopenia, Chronic Renal Failure
- Trial name
- MODIATIH (NCT05586854)
- Testing
- Hydrolink NV membrane
- Where
- France
- Volunteers
- 20 people
- Sponsor
- GCS Ramsay Santé pour l'Enseignement et la Recherche
Heparin-induced Thrombocytopenia
Cangrelor As Treatment for Cardiac Surgery Associated With Heparin Induced Thrombocytopenia
Heparin-induced thrombocytopenia (HIT) is a rare but serious immune complication of heparin exposure that paradoxically increases the risk of thrombosis.
- Trial name
- CATCH-IT (NCT07817680)
- Where
- France
- Volunteers
- 132 people
- Sponsor
- Société Française d'Anesthésie et de Réanimation
Aneurysmal Subarachnoid Hemorrhage, Neurobehavioral Manifestations
Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin
A Blind-adjudication Multi-center Phase II Randomized Clinical Trial of Continuous Low-dose Intravenous Heparin Therapy in Coiled Low-grade Aneurysmal Subarachnoid Hemorrhage Patients with Significant Hemorrhage Burden.
- Conditions
- Aneurysmal Subarachnoid Hemorrhage, Neurobehavioral Manifestations, Vasospasm, Intracranial, Intracranial Aneurysm
- Trial name
- ASTROH (NCT02501434)
- Testing
- Continuous Low-Dose IV Unfractionated Heparin Infusion
- Where
- 9 sites in United States
- Volunteers
- 88 people
- Sponsor
- Robert F. James
Heparin-Induced Thrombocytopenia
Heparin Antibodies in Intensive Care Unit Patients (HAICU)
Intensive care unit patients have multiple risk factors for venous thromboembolism. Venous thromboembolism leads to significant morbidity and can be fatal.
- Trial name
- NCT00283322
- Testing
- blood samples (2)
- Where
- 2 sites in United States
- Volunteers
- 185 people
- Sponsor
- The University of Texas Health Science Center, Houston
Heparin-induced Thrombocytopenia, HIT
Characterization and Quantification of Platelet/Leukocyte Aggregates in Patients With Suspected Heparin-induced Thrombocytopenia
The investigators would like to analyze platelet/leukoplak activation, quantify and morphologically characterize these aggregates using in vitro analysis, directly on whole blood from adult patients with suspected HIT.
- Conditions
- Heparin-induced Thrombocytopenia, HIT, Platelet Activation, Platelets
- Trial name
- HITSTREAM (NCT06033300)
- Testing
- blood sample
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Thrombocytopenia, Thrombosis
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
The purpose of this study is to evaluate the safe and effective dose of Argatroban for prophylaxis and/or treatment of thrombosis in pediatric patients with current or previous diagnosis of heparin-induced thrombocytopenia (HIT)…
- Trial name
- NCT00039858
- Testing
- Argatroban
- Where
- 13 sites in United States
- Volunteers
- 24 people
- Sponsor
- Encysive Pharmaceuticals
Suspected Heparin-Induced Thrombocytopenia
A Comparative Sudy Comparing Argatroban® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome
Compare Clinical Success and Costs in two Arms
- Trial name
- HIT (NCT00787332)
- Testing
- Desirudin or Argatroban®
- Where
- 24 sites in United States
- Volunteers
- 16 people
- Sponsor
- Canyon Pharmaceuticals, Inc.
Thrombocytopenia, Immune, Heparin Induced Thrombocytopenia
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a 12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia (HIT).
- Trial name
- NCT05785819
- Testing
- VLX-1005
- Where
- 14 sites in United States
- Volunteers
- 24 people
- Sponsor
- Veralox Therapeutics
Heparin-induced Thrombocytopenia
Pharmacogenomics of Heparin-Induced Thrombocytopenia
The purpose of this research is to identify genomic markers that can predict heparin-induced thrombocytopenia (HIT), which is a very serious side effect to heparin.
- Trial name
- PHIT (NCT02717039)
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- University of Arizona
Heparin-Induced Thrombocytopenia
Heparin-Induced Thrombocytopenia Score Card Study
Main Research Question: Can two new types of test, one called the 4T's score and the other called a rapid assay, help doctors correctly identify which patients are unlikely to have heparin-induced thrombocytopenia (HIT)? HIT is a…
- Trial name
- NCT00489437
- Testing
- ID-PaGIA Heparin/PF4 antibody test, Clinical Prediction Score-HIT Score Card
- Where
- Canada
- Volunteers
- 536 people
- Sponsor
- McMaster University
Heparin-induced Thrombocytopenia
Evaluation of the Intra-observer Agreement of the HEP Score in Surgical Intensive Care.
The main objective of this work is to assess the intraoperator reproducibility in the calculation of the HEP score in a population of intensive care patients.
- Trial name
- REPROHEP (NCT04782843)
- Testing
- HEP score assessement
- Volunteers
- 124 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Heparin-Induced Thrombocytopenia, Thrombosis
Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia
Heparin induced thrombocytopenia (HIT) is a kind of catastrophic thrombotic complications after the application of heparin. If HIT without treatment, death rate is as high as 30% to 50%.
- Conditions
- Heparin-Induced Thrombocytopenia, Thrombosis, Biomarkers
- Trial name
- NCT03269019
- Testing
- HIT with thrombosis
- Volunteers
- 200 people
- Sponsor
- Wuhan Asia Heart Hospital
Heparin-induced Thrombocytopenia, Heparin-induced Thrombocytopenia and Thrombosis
Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)
This research study is studying a drug as a possible treatment for heparin induced thrombocytopenia (HIT) or Heparin-induced Thrombocytopenia and Thrombosis (HITT). The drug involved in this study is apixaban.
- Trial name
- NCT03594045
- Testing
- Apixaban
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Massachusetts General Hospital
Thrombocytopenia, Thrombosis
Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)
The purpose of this study is to examine the safety and efficacy of Angiomax as an anticoagulation in patients with heparin-induced thrombocytopenia (HIT)/heparin-induced thrombocytopenia with thrombosis syndrome (HITTS)…
- Conditions
- Thrombocytopenia, Thrombosis, Cardiac Disease, Coronary Artery Bypass Surgery
- Trial name
- NCT00073580
- Testing
- Angiomax (bivalirudin) anticoagulant
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- The Medicines Company
Heparin-induced Thrombocytopenia
Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban
An Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects with Acute HIT (HITSOVA study)
- Trial name
- HITSOVA (NCT03809481)
- Testing
- Danaparoid Sodium, Argatroban
- Where
- 35 sites in United States, Bosnia and Herzegovina and 7 more
- Volunteers
- 7 people
- Sponsor
- Aspen Global Incorporated